RxDoctor Payments DataLook up a doctor →

Jarret Helstern, NP

Family · Skokie, ILNPI 1992169015

Payments from drug & device makers

$109,881in general payments, 2019–2025

Across 1,028 payments — averaging $106.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$53K
  • AbbVie$43K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Neurocrine Biosciences, Inc.$2K
  • Lundbeck LLC$1K
  • Supernus Pharmaceuticals, Inc.$1K
  • plus $7K from 33 others

What the payments were for

  • Consulting fees$1,3531%
  • Speaking & faculty fees$77,48171%
  • Travel & lodging$10,0929%
  • Food & beverage$20,76219%
  • Education$1940%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,881 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$16,600
Medicare patients
32
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl32$154,478
VraylarCariprazine Hcl24$37,493
Invega SustennaPaliperidone Palmitate12$32,342
OzempicSemaglutide28$30,782
RexultiBrexpiprazole12$26,115
MounjaroTirzepatide21$21,455
Lurasidone Hcl19$12,631
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine46$6,972
Lisdexamfetamine Dimesylate29$6,371
QuviviqDaridorexant Hcl11$5,168
Clozapine19$2,786
Aripiprazole39$2,637
Armodafinil18$1,886
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$1,826
Dextroamphetamine Sulfate23$1,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato, Invega Sustenna$491$186,82044 claims
AbbVieVraylar$42,747$37,49324 claims
Novo NordiskOzempic$23$30,78228 claims
Otsuka America Pharmaceutical, Inc.Rexulti$53,110$26,11512 claims
Lilly USA, LLCMounjaro$138$21,45521 claims
Idorsia Pharmaceuticals US IncQuviviq$189$5,16811 claims
Almatica Pharma LLCSertraline Hcl$69$25630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Skokie

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →